Natera, Inc. (NTRA) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
Natera (NTRA) Q2 2026: Signatera Clinical MRD Units Jump 56%, Unlocking Multi-Segment Momentum
August 07, 2026
23
Natera (NTRA) Q1 2026: Oncology Volumes Surge 55% as ASP Momentum Unlocks Margin Upside
May 08, 2026
24
Natera (NTRA) Q4 2025: MRD Clinical Units Surge 56%, Expanding Oncology Moat
February 28, 2026
22
Natera (NTRA) Q3 2025: Signatera Volumes Surge 56%, Fueling Guidance Reset and Margin Expansion
November 07, 2025
22
Natera (NTRA) Q2 2025: Signatera Volumes Jump 20,000 Units, Fueling $80M Guidance Raise
August 08, 2025
24
Natera (NTRA) Q1 2025: Signatera Clinical Volumes Jump 52% as ASP Expansion Drives Margin Gains
July 05, 2025
Natera (NTRA) Q4 2024: 53% Revenue Growth and 63% Gross Margin Highlight Operational Leverage and Market Expansion
February 27, 2025

Browse all companies